All Search Results
-
A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency
A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)
-
Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors (Explorer10)
Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors
-
Investigation Drug Study to Assess the Efficacy and Safety of NEXIUM for Treating Erosive Esophagitis
A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Subjects with Moderately to Severely Active Ulcerative Colitis
-
RESPONDR ™ TNF EMPOWER
RESPONDR ™ TNF EMPOWER
-
A RETROSPECTIVE CONTINUATION STUDY IN SMALL FIBER NEUROPATHY IN CHILDREN: PRESENTATION & CLINICAL FEATURES
A RETROSPECTIVE CONTINUATION STUDY IN SMALL FIBER NEUROPATHY IN CHILDREN: PRESENTATION & CLINICAL FEATURES
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
-
A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care
A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors
